MASIMO CORP (MASI)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for MASI
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MASI | CEO; Chief Executive Officer and Director | 58 | ["Has served as CEO of the Company since February 12, 2025", "President of Advanced Patient Monitoring Business (APM) at Edwards Lifesciences / Becton Dickinson from 2015 to 2025", "Inari Medical, Inc. (2019\u2013Present)", "Outset Medical, Inc. (2021\u20132024)", "Experienced global executive and board member with strategy, operating and finance leadership experience", "Inspirational leader with over 20 years of experience leading and transforming businesses through patient-focused innovation", "Deep Medical Device, and Operational experience developed during her roles at Medtronic, Edwards Lifescience and Becton Dickinson", "Successful track record of accelerating revenue growth by bringing new products to market", "Extensive experience leading and retaining top industry talent", "Deep existing relationships within the sector", "Over a decade of experience in Critical Care business at Edwards Lifesciences", "Led revenue growth through AI-driven solutions", "More than 20 years at Medtronic with leadership roles in corporate strategy, business development, and finance", "Served on the boards of Inari Medical and Outset Medical", "B.A. from the University of St. Thomas and M.B.A. from Harvard Business School"] | [] | 2025 |
Biography sourced from the proxy statement filing.
Catherine Szyman has served as our Chief Executive Officer and Director since February 2025. From September 2024 to February 2025, Ms. Szyman served as Worldwide President of Advanced Patient Monitoring at BD (Becton, Dickinson and Company) which was acquired from Edwards Lifesciences. Ms. Szyman led the Critical Care business at Edwards Lifesciences for over a decade beginning in 2014 through the acquisition by BD (Becton, Dickinson and Company) in September of 2024. While at Edwards, Ms. Szyman accelerated the revenue growth of the business by shifting to AI-driven solutions that aid clinicians in decision making and help patients return home to their families faster. Previously, Ms. Szyman spent more than 20 years at Medtronic, where she held positions with increasing levels of responsibility inside and outside the U.S., including leadership roles in corporate strategy, business development and finance, and as the worldwide president of both the Endovascular and Diabetes business units. Ms. Szyman previously served on the boards of Inari Medical (Nasdaq: NARI) starting in 2019 and Outset Medical (Nasdaq: OM) from 2021 to 2024. Ms. Szyman received a B.A. from the University of St. Thomas and an M.B.A. from Harvard Business School.